Ticagrelor or prasugrel in patients with acute coronary syndrome with off-hour versus on-hour presentation: a subgroup analysis of the ISAR-REACT 5 trial

ConclusionsIn patients with ACS planned to undergo an invasive treatment strategy, time of presentation (off-hours vs. on-hours) does not interact significantly with the relative efficacy and safety of ticagrelor vs. prasugrel.Clinical trial registration.NCT01944800.Graphical abstract

http://rd.springer.com/10.1007/s00392-022-02040-z

Source: Clinical Research in Cardiology - July 5, 2022 Category: Cardiology Source Type: research